Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia Timmers

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Nature|July 3, 2008
Mouse development with a single E2F activatorShih-Yin Tsai, Rene Opavsky, Nidhi Sharma, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2020
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal CancerChristina Wu, Terence M Williams, Ryan Robb, et al.
Thyroid : Official Journal of the American Thyroid Association|June 6, 2022
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter TrialNaifa L Busaidy, Bhavana Konda, Lai Wei, et al.
Cell Reports|May 28, 2019
Two Distinct E2F Transcriptional Modules Drive Cell Cycles and DifferentiationMaria C Cuitiño, Thierry Pécot, Daokun Sun, et al.
Oncoimmunology|December 29, 2025
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> modelsPhurin Areesawangkit, Karen Pei-Yi Fong, Emma Niemeyer, et al.
Cold Spring Harbor Molecular Case Studies|August 3, 2019
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsyMelanie A Krook, Russell Bonneville, Hui-Zi Chen, et al.
Cell Reports. Medicine|November 10, 2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinomaSixue Liu, Hannah M Knochelmann, Shirley H Lomeli, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Nature|July 3, 2008
Mouse development with a single E2F activatorShih-Yin Tsai, Rene Opavsky, Nidhi Sharma, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2020
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal CancerChristina Wu, Terence M Williams, Ryan Robb, et al.
Thyroid : Official Journal of the American Thyroid Association|June 6, 2022
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter TrialNaifa L Busaidy, Bhavana Konda, Lai Wei, et al.
Cell Reports|May 28, 2019
Two Distinct E2F Transcriptional Modules Drive Cell Cycles and DifferentiationMaria C Cuitiño, Thierry Pécot, Daokun Sun, et al.
Oncoimmunology|December 29, 2025
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> modelsPhurin Areesawangkit, Karen Pei-Yi Fong, Emma Niemeyer, et al.
Cold Spring Harbor Molecular Case Studies|August 3, 2019
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsyMelanie A Krook, Russell Bonneville, Hui-Zi Chen, et al.
Cell Reports. Medicine|November 10, 2021
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinomaSixue Liu, Hannah M Knochelmann, Shirley H Lomeli, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
Gynecologic Oncology|November 15, 2017
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancerCasey M Cosgrove, David L Tritchler, David E Cohn, et al.
Pageof 4